🇺🇸 FDA
Pipeline program

BPX-601

BP-012

Phase 1 mab terminated

Quick answer

BPX-601 for Metastatic Castration-resistant Prostate Cancer is a Phase 1 program (mab) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Metastatic Castration-resistant Prostate Cancer
Phase
Phase 1
Modality
mab
Status
terminated

Clinical trials